Anika Therapeutics (ANIK) Income towards Parent Company (2010 - 2025)

Anika Therapeutics (ANIK) has 16 years of Income towards Parent Company data on file, last reported at -$1.5 million in Q4 2025.

• Income towards Parent Company for Q4 2025 came in at -$1.5 million, up 92.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $14000.0 (up 100.03% YoY), and the FY2025 annual result was -$901000.0, up 98.11% from the prior year.
• Income towards Parent Company retreated to -$1.5 million in Q4 2025 per ANIK's latest filing, from $846000.0 in the prior quarter.
• Over five years, Income towards Parent Company peaked at $17.1 million in Q4 2023 and troughed at -$28.1 million in Q3 2024.
• A 5-year average of -$2.8 million and a median of -$2.0 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company sank 845.88% in 2022, then surged 188.56% in 2024.
• A 5-year view of Income towards Parent Company shows it stood at -$10.7 million in 2021, then soared by 156.56% to $6.1 million in 2022, then jumped by 181.25% to $17.1 million in 2023, then sank by 213.33% to -$19.4 million in 2024, then soared by 92.21% to -$1.5 million in 2025.
• Business Quant data shows ANIK's Income towards Parent Company at -$1.5 million in Q4 2025, $846000.0 in Q3 2025, and $677000.0 in Q2 2025.